Investigation of a Novel Cosmeceutical to Reduce the Visible Signs of Cutaneous Aging

Tomorrowlabs GmbH40 enrolled

Overview

Tomorrowlabs has developed a revolutionary cosmeceutical formulation to rejuvenate aging skin. Tomorrowlabs is conducting this research to study whether this cosmeceutical can reduce the visible signs of cutaneous aging.

It is proposed to study a cosmeceutical formulation designed to reduce the visible signs of cutaneous aging. It is expected that daily application of the formulation may minimize wrinkles and fine lines of the face.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Aging

Interventions

Tomorrowlabs cosmeceutical formulationOTHER

Sham cosmeceutical formulationOTHER

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers who desire to improve their appearance by reducing the visible signs of cutaneous aging in the face Exclusion Criteria: * Subjects who have undergone facial plastic surgery or aesthetic dermatology treatments to the face (such as fillers and neuromodulators) in the past 6 months * Subjects with a history of collagen vascular disease, cutis laxa, connective tissue disease, psoriasis, or lupus. * Subjects diagnosed with scleroderma. * Subjects with a body mass index (BMI) \> 30. * Subjects taking steroid therapy.

Outcomes

Primary Outcomes

Validated Assessment Scales for Age-related Changes of the Face

A reliable tool for valid and reproducible assessment of the aging process in various face areas will be employed by our independent panel of assessors to scale the primary outcome. (1-3)

Time frame: 3 months

Secondary Outcomes

Skin quality assessment

The skin scope uses black light and magnification to show variety of skin imperfections that are undetectable with the naked eye such as dry and thin skin

Time frame: 3 months

Subject Satisfaction With the Results

Self assessment questionnaire

Time frame: 3 months

Central Contacts

Dominik Thor, PhD

CONTACT

+4369911917515 dominik@thor.at

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.